Table 1.
Patient characteristics
| Healthy individuals | HSCT‐alone | HSCT with third‐party VST | P‐value | |
|---|---|---|---|---|
| Number of individuals | 13 | 13 | 8 | |
| Age (median, range) | 55 (28–83) | 55 (32–70) | 58.5 (12–52) | 0.55 |
| Sex (M:F) | 9:4 | 5:8 | 4:4 | 0.67 |
| Diagnosis | ||||
| AML | 10 | 5 | 0.78 | |
| ALL | 1 | 1 | ||
| Other malignant | 2 | 2 | ||
| Conditioning | ||||
| MAC | 3 | 2 | 0.92 | |
| RIC | 10 | 6 | ||
| T‐cell depletion | 7 | 7 | 0.17 | |
| Donor | ||||
| Cord | 0 | 1 | 0.35 | |
| Haplo | 1 | 0 | ||
| MUD | 10 | 5 | ||
| Sib | 2 | 2 | ||
| CMV serostatus (R/D) | ‐ | |||
| Neg/Neg | 3 | 0 | 0.16 | |
| Neg/Pos | 0 | 0 | ||
| Pos/Neg | 6 | 6 | ||
| Pos/Pos | 4 | 2 | ||
| CMV reactivation | 9 (69%) | 8 (100%) | 0.08 | |
| Median day of reactivation (range) | 31 (25–45) | 29 (17–43) | 0.33 | |
| CMV DNA log10AUC a (range) | 2.4 (0–4.34) | 5.7 (5.06–6.42) | 0.001 | |
| CMV tissue disease | 1 (8%) | 1 (13%) | 1.0 | |
| Acute GVHD | ||||
| Overall (grade 2–4) | 6 (46%) | 2 (25%) | 0.40 | |
| Severe (grade 3–4) | 3 (23%) | 1 (13%) | 1.0 | |
| Chronic GVHD | 6 (46%) | 3 (37%) | 1.0 | |
| Relapse | 2 (15%) | 1 (13%) | 1.0 | |
| Death | 0 (0%) | 2 (25%) | 0.13 | |
| Number of samples | 13 | 42 | 24 | |
| Collection day of sample post‐transplant, median (range) | 74.5 (26–132) | 128 (63–255) | < 0.0001 | |
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; CMV, cytomegalovirus; GVHD, graft‐versus‐host disease; Haplo, haploidentical; MAC, myeloablative conditioning; MUD, matched unrelated donor; R/D, recipient/donor; RIC, reduced intensity conditioning; Sib, sibling.
a
Mean log10 of CMV viral load area under the curve (AUC) in copies/mL prior to the first study timepoint. AUC is used as a measure of total viral antigen exposure.